Phase I non-myeloblative trial with 90Y-humanized MN-14 (anti-CEA) [carcinoembryonic antigen] antibody [labetuzumab Y-90] for relapsed or refractory small cell lung cancer (SCLC).
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2009
At a glance
- Drugs Labetuzumab Y-90 (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 29 Sep 2005 New trial record.